© Parkinson’s UK, July 2019. Parkinson’s is the operating name of the Parkinson’s Disease Society of the United Kingdom. A charity registered in England and Wales (258197) and in Scotland (SC037554)

Parkinson's UK

News

12 Mar 2018

KEAPSTONE THERAPEUTICS was created in February 2017 as a single-asset virtual biotech company, spun out of University of Sheffield with seed funding of £1M provided by Parkinson’s UK.  Keapstone is dedicated to developing a novel series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson’s and amyotrophic lateral sclerosis (ALS).  In...

8 Mar 2018

A new collaboration in the efforts to find a new drug candidate to combat Parkinson’s has been announced in the UK today.


The collaboration, formed by leading charity Parkinson’s UK, contract innovation and research organization, Selcia (part of Eurofins), and computational chemistry software and services provider, Cresset Discovery Services, is centred on creating n...

24 Jan 2018

UK-based charity, Parkinson’s UK is set to provide more than $1million in funding to US biotech company, Neurolixis, to accelerate the development of a promising new drug for people with Parkinson’s.

The funding, to be spread over a twelve-month period, will support final pre-clinical studies for NLX-112, a novel serotonin 5-HT1A receptor agonist for the treatment of...

27 Nov 2017

Parkinson’s UK is pleased to announce that it has agreed to provide up to £320,000 additional funding to Keapstone Therapeutics to expand its current research programme to develop molecules with the potential to create drugs that can slow or stop the progression of Parkinson’s.
 

Keapstone Therapeutics was launched in March 2017 by Parkinson’s UK and the University of...

24 Oct 2017

Please note that we have now filled the vacant positions on our Drug Discovery Advisory Panel. If you would like to keep up with future opportunities to work with us please sign up to Synapse - the Parkinson's UK enewsletter for researchers.

The Parkinson’s UK Virtual Biotech selects and manages projects at the drug discovery and early clinical development stages, to...

14 Aug 2017

Parkinson’s UK is pleased to announce the release of the next tranche of the £1million funding to Keapstone Therapeutics.
 

Keapstone Therapeutics was launched in March 2017 by Parkinson’s UK and the University of Sheffield.  It is part of Parkinson’s UK’s new Virtual Biotech venture and combines world-leading research from the University with funding and expertise fr...

Please reload